We have located links that may give you full text access.
Regulation of chemokine expression by cyclosporine A in alveolar macrophages exposed to hypoxia and reoxygenation.
Annals of Thoracic Surgery 2002 September
BACKGROUND: We have recently demonstrated a role for selected chemokines in a rat model of lung ischemia reperfusion injury (LIRI). We have further shown that pretreatment with cyclosporine A (CSA) is protective. The precise cellular events regulating this model are unknown. The alveolar macrophage (AM) is a key effector cell in multiple models of acute lung injury, and it likely plays a central role in LIRI as well. The present studies were undertaken to determine whether CSA functions in part by modifying the chemokine response of AMs to hypoxia and reoxygenation in vitro.
METHODS: Alveola macrophages were rendered hypoxic (0.5%) for 2 hours and reoxygenated for 6 hours. The secreted chemokine content in the media was quantified by enzyme-linked immunosorbent assay, and nuclear protein was analyzed after electro-mobility shift assay. When employed, CSA was administered 30 minutes before hypoxia.
RESULTS: Alveolar macrophages demonstrated a marked increase in the secretion of the chemokines, MIP-2, MIP-1alpha, CINC, and MCP-1, in response to hypoxia and reoxygenation. This increase was dependent on mRNA transcription and de novo protein synthesis. It was also blocked by a specific inhibitor of the nuclear translocation factor, NF-kappaB. Pretreatment with CSA (500 ng/mL) significantly reduced expression of chemokines and activation of NF-kappaB.
CONCLUSIONS: Cyclosporine A attenuates the chemokine response of AMs in vitro to hypoxia and reoxygenation at the pretranscriptional level through modulation of NF-kappaB. These findings suggest the potential mechanism of action of CSA's protective effects in lung ischemia reperfusion injury.
METHODS: Alveola macrophages were rendered hypoxic (0.5%) for 2 hours and reoxygenated for 6 hours. The secreted chemokine content in the media was quantified by enzyme-linked immunosorbent assay, and nuclear protein was analyzed after electro-mobility shift assay. When employed, CSA was administered 30 minutes before hypoxia.
RESULTS: Alveolar macrophages demonstrated a marked increase in the secretion of the chemokines, MIP-2, MIP-1alpha, CINC, and MCP-1, in response to hypoxia and reoxygenation. This increase was dependent on mRNA transcription and de novo protein synthesis. It was also blocked by a specific inhibitor of the nuclear translocation factor, NF-kappaB. Pretreatment with CSA (500 ng/mL) significantly reduced expression of chemokines and activation of NF-kappaB.
CONCLUSIONS: Cyclosporine A attenuates the chemokine response of AMs in vitro to hypoxia and reoxygenation at the pretranscriptional level through modulation of NF-kappaB. These findings suggest the potential mechanism of action of CSA's protective effects in lung ischemia reperfusion injury.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app